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Abstract Cellular functions accompanying establishment
of premature senescence in methotrexate-treated human
colon cancer C85 cells are deciphered in the present study
from validated competitive expression microarray data,
analyzed with the use of Ingenuity Pathways Analysis
(IPA) software. The nitrosative/oxidative stress, inferred
from upregulated expression of inducible nitric oxide
synthase (iNOS) and mitochondrial dysfunction-associated
genes, including monoamine oxidases MAOA and MAOB,
β-amyloid precursor protein (APP) and presenilin 1
(PSEN1), is identified as the main determinant of signaling
pathways operating during senescence establishment. Acti-
vation of p53-signaling pathway is found associated with
both apoptotic and autophagic components contributing to
this process. Activation of nuclear factor κB (NF-κB),
resulting from interferon γ (IFNγ), integrin, interleukin 1β
(IL-1β), IL-4, IL-13, IL-22, Toll-like receptors (TLRs) 1, 2
and 3, growth factors and tumor necrosis factor (TNF)
superfamily members signaling, is found to underpin
inflammatory properties of senescent C85 cells. Upregula-
tion of p21-activated kinases (PAK2 and PAK6), several
Rho molecules and myosin regulatory light chains
MYL12A and MYL12B, indicates acquisition of motility
by those cells. Mitogen-activated protein kinase p38 MAPK
β, extracellular signal-regulated kinases ERK2 and ERK5,
protein kinase B AKT1, as well as calcium, are identified as
factors coordinating signaling pathways in senescent C85
cells.
Keywords High-dose methotrexate.Colorectal
adenocarcinoma.Drug-induced senescence.Expression
microarrays.Signaling pathways
Introduction
Cellular senescence is a stable and conditionally reversible
growth arrest evoked by stress signals culminating in the
induction of DNA damage response [1, 2]. It is viewed as a
metabolically active state of hypermitogenic stimulation
counterbalanced by induction of cyclin-dependent kinase
(CDK) inhibitors [1]. Apart from being originally described
as a replicative form of senescence occurring in normal
cells that have reached a division limit, senescence induced
by activated oncogenes and premature form of senescence,
also termed stress-induced or accelerated, or else
senescence-like growth arrest, were also identified [3, 4].
Premature senescence may proceed in normal, as well as in
cancer cells, and in regard to the latter it is of interest as a
consequence of DNA damage brought about by radio- and
chemotherapy [4]. Two main issues concerning therapy-
induced senescence that require elucidation, before it can be
exploited as an anticancer strategy refer to (i) senescence
associated secretory phenotype (SASP), i.e., molecules
secreted by senescent cells among which growth- and
inflammation-promoting as well as extracellular matrix
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of the state of senescence [4, 5]. In view of the reports
demonstrating that populations of cancer cells driven into
therapy-induced senescence are able to regain proliferative
functions, senescence associated with controlled cellular
self-destruction process, autophagy, is postulated to under-
pin tumor dormancy in vivo [6].
Our previous work documented premature senescence as
the sole response of human colon cancer C85 cells to the
treatment with high dose classic antifolate, methotrexate
[7–9]. C85 cells are driven into senescence by the drug
treatment despite being also capable of undergoing apopto-
sis [8]. The present study was aimed at delineation of
cellular functions, inferred from the pattern of activated
signaling pathways, determining establishment of senescent
phenotype in this cellular system. It can be hypothesized
that in C85 cells exposed to methotrexate interference with
nitric oxide (NO) signaling acts as a molecular trigger for
nitrosative/oxidative stress generation upon senescence
initiation. Maintenance of senescent phenotype is subse-
quently executed by autostimulatory action of SASP
components and paracrine cytokine stimulation, both
determining pro-inflammatory characteristics of those cells.
The ability of C85 cells to reconstitute, after methotrexate
removal, a cell line displaying the same kinetics of the drug
sensitivity [7], correlated with autophagy and expression of
ECM degrading SASP factors, indicates that in these
cellular settings premature senescence might serve to
enable treatment evasion rather than cancer eradication.
This corresponds with known inefficacy of methotrexate
applied as a single agent for colon cancer treatment.
Pathway-directed intervention is postulated to be a future
strategy in cancer treatment, as despite multitude mutations
of the genomes of cancer cells, limited is the number of
intracellular signaling pathways underlying oncogenic
transformation and consequently, tumor response to therapy
[10, 11]. Functional validation in various colon cancer cells
of the signaling pathways herein identified as pertaining to
the establishment of methotrexate-induced senescence in
C85 cells may allow us to assess a putative therapeutic
strategy aimed at the ultimate destabilization of the state of
senescence rather than its maintenance.
Material and methods
Cell culture
Human colorectal adenocarcinoma C85 cells, originating
from primary untreated tumor classified as Duke’s stage D
disease [12], were maintained in RPMI 1640 medium
(Lonza, Belgium), supplemented with 10% fetal bovine
serum (Sigma-Aldrich), 100 units/ml penicillin and 100 μg/
ml streptomycin (both from LGC Promochem). Cells were
exposed for 48 h to 1 μM methotrexate (Schircks
Laboratory, Switzerland), a drug concentration
corresponding to that clinically attained with the high dose
methotrexate therapy [13]. This treatment variant was
designated MTX48. Recovery of C85 cells after drug
exposure was carried out for 96 h in the regular medium
and this treatment variant was designated R96.
Expression microarray analysis
Total RNA was isolated using RNeasy Mini kit (Qiagen).
cRNA labeling was performed with the use of Low RNA Input
Linear Amplification kit (Agilent Technologies). Two experi-
mental variants of competitive hybridizations were carried out
with the Human whole genome expression microarrays
(Agilent Technologies): (i) MTX48 cells vs. untreated cells
and (ii) R96 cells vs. untreated cells. Two-color hybridizations,
run in quadruplicates with dye swap between duplicates of the
same variant, were performed according to Agilent Two-Color
Microarray-Based Analysis protocol. Axon GenePix 4000B
scanner and GenePix software (Molecular Devices) were used
for feature extraction. Statistical evaluation employing Stu-
dent’s t-test was performed in Acuity software (Molecular
Devices). Upregulation of particular gene expression level in
either variant was inferred from positive log2 ratio value. The
data were submitted to ArrayExpress database and are
available with E-MEXP-3018 accession at http://www.ebi.ac.
uk/arrayexpress.
Signaling pathways analysis
Data sets of statistically evaluated microarray results were
loaded into Ingenuity Pathways Analysis (IPA) software
(Ingenuity Systems, www.ingenuity.com). Two core analyses
were run individually for gene lists corresponding to gene
expression profiles of MTX48 and R96 treatment variants. In
each analysis expression parameters cut-offs were set at 0.5
for log2 ratio and 0.05 for p value and, as the aim was to
identify activated pathways, only upregulated identifiers,
considered indicative of those activated pathways, were
included. Particular pathway-eligible molecules were de-
duced from an overlay of IP A canonical pathways, built
within the software, with gene lists enriched according to the
applied expression parameters cut-offs. Activated signaling
pathways predominant for MTX48 and R96 experimental
variants based on statistical significance (p value), were
inferred from a comparison analysis of the two core analyses.
Quantitative RT-PCR
Total RNA was isolated using RNeasy Mini kit (Qiagen).
Reverse transcription was performed using High-Capacity
966 Tumor Biol. (2011) 32:965–976cDNA Reverse Transcription kit and real-time polymerase
chain reaction (PCR), using Power SYBR Green PCR Master
Mix, both from Applied Biosystems. The primers designed
with the use of PrimerExpress software (Applied Biosystems)
are listed in Table S1. Target gene expression level,
normalized to the expression of cyclophilin D (peptidylprolyl
isomerase D, PPID), used as a reference gene, was calculated
applying comparative threshold cycle (CT)m e t h o d .
Results
V alidation of the experimental model
C85 cells exposed to methotrexate for 48 h (MTX48)
constitute a homologous population of apparently enlarged
cells containing irregular nucleoli and staining negative for
senescence marker, senescence-associated (SA)-β-galacto-
sidase activity (Fig. 1). These cells are considered to be
committed to senesce and thus to correspond to the
senescence initiation phase. The cell population recovered
for 96 h after methotrexate treatment (R96) consists of two
subpopulations, one constituting a small fraction of cells
resembling the untreated C85 cells, and the other, being a
dominant fraction of large cells, having nucleoli more
regular in shape than those in cells of MTX48 variant and
staining positive for SA-β-galactosidase activity. The latter
subpopulation is considered to represent cells being at the
senescence maintenance phase. As in the population of R96
treatment variant, regrowing cells are less represented, the
transcriptome corresponding to this population is enriched
in those transcripts whose expression is upregulated in
senescent cell fraction. Only upregulated genes were
included in the analysis of signaling pathways activated
during senescence initiation and maintenance phases. Thus,
the pathways inferred for C85 cells of R96 treatment
variant, in relation to the untreated cells, correspond
specifically to the fraction of cells at the senescence
maintenance phase. This is supported by the expression
pattern of cell cycle checkpoint regulatory genes, cyclins D,
CDK inhibitors p21
waf1/cip1 and p15 being upregulated, and
CDK4, cyclins B, cell division cycle (cdc) cdc2 and
cdc25C being downregulated in the population of R96
cells [9]. The signaling pathways specific for each of the
senescence establishment phases, initiation and mainte-
nance, respectively, are listed in Table 1.
Apoptosis and autophagy accompany establishment
of methotrexate-induced senescence in C85 cells
p53 effectors, including apoptosis-inducing genes and
essential for autophagy damage-regulated autophagy mod-
ulator gene (DRAM), are upregulated predominantly during
senescence initiation phase (Table 2). Other genes involved
in autophagy remain upregulated also during senescence
maintenance phase. Genes regulating p53 transcriptional
activity, including its binding partners (BRCA1 and
PLAGL1) and modifiers, acetyltransaferase PCAF and
ubiquitin ligase transcript variant MDM2b, are induced
during the initiation phase. MDM2 transcript variant is
upregulated during the maintenance phase (Table 2). Upre-
gulated throughout the whole process of senescence
establishment p53-inducible gene 3 (PIG3), and glycolysis
and apoptosis regulator TIGAR, are known to be associated
specifically with oxidative stress [14, 15].
Nitrosative/oxidative stress and antioxidant response
are manifested during establishment
of methotrexate-induced senescence in C85 cells
Upregulation of iNOS (NOS2A) isoform occurs during
both senescence initiation and maintenance phases (Table 3).
During senescence initiation eNOS (NOS3) isoform is also
upregulated. Senescent C85 cells display induced expres-
sion of neutrophil cytosolic factor 4 (NCF4, p40 phox), a
regulatory molecule of NADPH oxidase complex involved
in the production of reactive oxygen species (ROS) on the
macrophage plasma or phagosome membrane. Xenobiotic
metabolism signaling pathway is not surprisingly activated
in C85 cells exposed to methotrexate (Table 1). Among
Fig. 1 C85 cells populations in
the course of establishment of
methotrexate-induced senes-
cence. Cells were colorimetri-
cally assayed for senescence-
associated β-galactosidase ac-
tivity performed as previously
described [8] and stained with
Accustain May–Grunwald solu-
tion (Sigma-Aldrich). The
images were taken with Olym-
pus IX70 microscope at ×100
magnification
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Initiation Maintenance
p53 signaling 3.36×10
−8 1.72×10
−2
Interferon signaling 1.54×10
−6 6.99×10
−7
Integrin signaling 8.72×10
−5 8.58×10
−9
VDR/RXR activation 1.57×10
−4 1.98×10
−3
Germ cell–Sertoli cell junction signaling 1.82×10
−4 1.41×10
−8
Regulation of actin-based motility by Rho 1.96×10
−4 6.00×10
−6
Apoptosis signaling 2.31×10
−4 3.24×10
−3
Caveolar-mediated endocytosis 1.64×10
−3 7.04×10
−6
p38 MAPK signaling 1.95×10
−3 1.91×10
−3
Xenobiotic metabolism signaling 2.62×10
−3 3.16×10
−2
Death receptor signaling 5.53×10
−3 9.60×10
−6
ERK/MAPK signaling 9.87×10
−3 5.93×10
−6
Semaphorin signaling in neurons 1.00×10
−2 3.78×10
−6
Production of nitric oxide and reactive oxygen species in macrophages 1.93×10
−2 9.75×10
−6
PI3K/AKTsignaling 2.37×10
−2 6.65×10
−6
Calcium signaling 5.47×10
−2 3.53×10
−2
Clathrin-mediated endocytosis 1.05×10
−1 3.27×10
−5
ERK5 signaling 3.38×10
−1 6.85×10
−3
Table 1 Predominant signaling
pathways operating in C85 cells
during establishment of
methotrexate-induced senes-
cence, as inferred from IPA
software
The p value for statistical
significance of each pathway is
given.
Table 2 Molecules involved in p53-dependent cellular processes and regulation of p53 activity whose expression is upregulated in C85 cells
during establishment of methotrexate-induced senescence
Process Molecules
p53-dependent process
Apoptosis induction APAF1, BAX, DR4, DR5, FAS, LRDD, NOXA, PERP , PIG3, PUMA, TP53INP1
Angiogenesis inhibition SERPINB5, THBS1
Autophagy induction DRAM
Cell cycle arrest CDKN1A, Cyclin G, GADD45A, GADD45B, GADD45G, SFN
Cell survival BCL2L1
DNA repair PCNA, RRM2B
Glycolysis inhibition TIGAR
Senescence PAI-1
Regulation of p53 activity BRCA1, MDM2, MDM2b, PCAF, PLAGL1
Autophagy ATG12, ATG16L1, A TG16L2, ATG4A, A TG4B, A TG4D, BECN1, MAP1LC3B
Apoptosis regulation and execution BAK1, CASP7, CASP9, CASP10, CFLAR, LMNA, SPTAN1
The relevant molecules were inferred from the canonical p53 and apoptosis signaling pathways implemented in IPA software and in Ref. [56]. The
molecules upregulated during both senescence initiation and maintenance phases are printed bold, upregulated during the initiation phase are
printed with a regular font and upregulated during the maintenance phase are underlined.
AP AF1 apoptotic peptidase activating factor, ATG autophagy-related gene, BAK1 BCL2-antagonist/killer 1, BAX BCL2-associated X protein, BCL2L1
BCL2-like 1 nuclear gene encoding mitochondrial protein (Bcl-xL), BECN1 beclin 1, BRCA1 breast cancer 1, DRAM damage-regulated autophagy
modulator, CASP7/9/10 caspase 7/9/10, CDKN1A p21
waf1/cip1, CFLAR FLAME-1 (FLIP), DR4/5 death receptor 4/5, F AS TNF receptor superfamily,
member 6, GADD45A/B/G growth arrest and DNA-damage-inducible alpha/beta/gamma, LMNA lamin A/C, LRDD leucine-rich repeats and death
domain containing (PIDD), MAP1LC3B microtubule-associated protein 1 light chain 3 beta, NOXA phorbol-12-myristate-13-acetate-induced protein 1
(PMAIP1), P AI-1 plasminogen activator inhibitor type 1 (SERPINE2), PCAF p300/CBP-associated factor, PCNA proliferating cell nuclear antigen,
PERP TP53 apoptosis effector, PIG3 tumor protein p53 inducible protein 3 (TP53I3), PLAGL1 pleiomorphic adenoma gene-like 1 (ZAC1), PUMA
p53 upregulated modulator of apoptosis (BBC3), RRM2B ribonucleotide reductase M2B, SERPINB5 serpin peptidase inhibitor (maspin), SFN stratifin
(14-3-3 sigma), SPTAN1 spectrin; TP53INP1 tumor protein p53 inducible nuclear protein 1 (Teap), TIGARTP53-inducible glycolysis and apoptosis
regulator (C12ORF5), THBS1 thrombospondin 1. Corresponding microarray data are presented in Table S2
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MAOA and MAOB genes may provide a putative link to
mitochondrial dysfunction and, consequently, intensified
ROS formation [16, 17]. Mitochondrial dysfunction may
also be potentiated during senescence maintenance due to
increased expression of β-amyloid precursor protein (APP)
gene, γ-secretase-regulating presenilin 1 (PSEN1) mole-
cule, as well as two other mitochondrial factors being
electron donors for complex I, glycerol-3-phosphate and
oxoglutarate dehydrogenases (GPD2 and KGDH) (Table 3).
Genes encoding cellular antioxidant defense enzymes,
being effector molecules in nuclear factor-erythroid 2-
related factor 2 (Nrf2)-mediated signaling, which consti-
tutes a part of xenobiotic signaling pathway, are upregulated
predominantly during senescence maintenance phase.
Acquisition of pro-inflammatory functions by C85 cells
during establishment of methotrexate-induced senescence
iNOSexpressionisconsideredahallmarkofimmuneresponse
[18]. Its upregulation during senescence establishment in C85
cells may proceed due to IFNγ signaling mediated by signal
transducer and activator of transcription STA T1 and STA T2
(not shown) molecules, as well as interferon regulatory factor
1 (IRF1), all those factors upregulated during senescence
initiation and maintenance phases (Table 5). IFNγ receptor 1
(IFNGR1) is upregulated only during the maintenance phase
(Fig. 4). Inducible nitric oxide synthase (iNOS) upregulation
during senescence maintenance may also be mediated by
nuclear factor κB( N F - κB), activated due to autocrine action
of molecules secreted by senescent C85 cells, including IL-
1β, TNFSF10, TNFSF15 and an array of growth factors. It
may also be executed due to activation of IL4/IL13 and IL22
receptors, as well as integrins and TLRs (Fig. 2). Addition-
ally, activation of transmembrane NADPH oxidase complex
(vide supra), points to a property of senescent C85 cells to
elicit immunological response. Inflammatory phenotype of
C85 cells during senescence establishment is also associated
with STA T-mediated upregulation of ECM-modulating
enzymes. Those include plasminogen activator urokinase
(PLAU), matrix metallopeptidase MMP1 and metallopepti-
dase inhibitor TIMP3, serving to control the activity of
MMPs (Table S6). Other genes involved in ECM degradation
whose expression is induced in senescent C85 cells, include
NF-κB-dependent tissue plasminogen activator PLA T
(Fig. 2), and associated with various types of cancer matrix
metallopeptidases MMP7, MMP10 and MMP15 (Table S6).
Apart from pro-inflammatory action stimulation of TNF
receptors also induces apoptosis [19]. At the point of
apoptosis regulation, death receptor signaling interconnects
with p53 signaling pathway.
Cytoskeleton remodeling and endocytic pathways underlie
motile functions of C85 cells during maintenance phase
of methotrexate-induced senescence
Signaling pathways specifying cell adhesive interactions and
cytoskeletal dynamics,areactivatedinC85cellspredominantly
during the maintenance phase of senescence, indicating
acquisitionofmotility(Table1,F i g .3). Cell-to-cell interactions
also play a role in senescent C85 cells, as molecules involved
in germ cell–S e r t o l ic e l l[ 20] and also general tight-junction
formation, including catenins CTNNA1 and CTNND1,
claudins (CLDN1,4,7 and 23), cingulin, occludin and zona
occludens proteins TJP1 and TJP3, are also upregulated (Table
S6). Importance of intercellular connections points to putative
interaction between senescent cells and small descendant,
regrowing cells present in the population recovering after
methotrexate treatment (Fig. 1). Activation of two endocytic
pathways, caveolar- and clathrin-mediated endocytosis, occurs
Table 3 Molecules involved in nitrosative/oxidative stress generation and antioxidant response whose expression is upregulated in C85 cells
during establishment of methotrexate-induced senescence
Functional group Molecules
NO producing enzymes NOS2A, NOS3
NADPH–oxidase complex regulatory molecule (transmembrane) NCF4
Phase I xenobiotic detoxification enzymes associated with mitochondrial dysfunction MAOA, MAOB
Other mitochondrial dysfunction-associated factors APP , COX6B2, GPD2, KGDH, NDUFAF1, PSEN1
Nrf-2-dependent antioxidant defense enzymes FTH1, HMOX1, PRDX1, TRXR1, SOD3, SQSTM1
Functional assignment of selected molecules was performed in IPA software. The molecules upregulated during both senescence initiation and
maintenance phases are printed bold, upregulated during the initiation phase are printed with a regular font and upregulated during the
maintenance phase are underlined APP amyloid β (A4) precursor protein, COX6B2 cytochrome c oxidase subunit VIb polypeptide 2, FTH1
ferritin heavy polypeptide 1, GPD2 glycerol-3-phosphate dehydrogenase 2, HMOX1 heme oxygenase 1 (HO-1), KGDH oxoglutarate
dehydrogenase, MAOA/MAOB monoamine oxidase A/B, NCF4 neutrophil cytosolic factor 4 (p40 phox), NDUF AF1 NADH dehydrogenase
(ubiquinone) 1 alpha subcomplex, assembly factor 1, NOS2A/NOS3 inducible (iNOS)/endothelial (eNOS) nitric oxide synthase, PRDX1
peroxiredoxin 1, PSEN1 presenilin 1, TRXR1 thioredoxin reductase 1, SOD3 superoxide dismutase 3, SQSTM1 sequestosome 1. Corresponding
microarray data are presented in Table S3
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genes are upregulated during senescence initiation and
maintenance phases (Table S6). Of note is that oxidative
stress-induced premature senescence of human epithelial cells
was shown to depend on upregulation of caveolin 1 gene
transcription [21]. Under oxidative stress, phosphorylated
caveolin 1 associated with epidermal growth factor receptor
was found to determine the prolonged activation of the latter
[22]. Apart from endocytosis, clathrin was also shown to
participate in early autophagosome formation [23].
p38 MAPK β, ERK2, ERK5, AKT1 and calcium mediate
the main intracellular signaling pathways operating in C85
cellsduringestablishmentofmethotrexate-inducedsenescence
Signaling cascades, described above as pertaining to senes-
cence establishment in C85 cells treated with methotrexate
converge on p38 MAPK signaling, important during both
senescence initiation and maintenance phases, as well as
ERK1/2, ERK5 and PI3K/AKTsignaling, important predom-
inantly during the maintenance phase (Table 1, Fig. 4).
Additionally, vitamin D is identified as an important
signaling factor leading to upregulated expression of
platelet-derived growth factor alpha (PDGFA), several
growth-suppressive molecules and calcium transporting
transient receptor potential cation channel gene (TRPV6)
(Tables 1 and 4). At the senescence initiation phase,
upregulated expression of inositol 1,4,5-trisphosphate (IP3)
receptors indicates the importance of calcium as a second
messenger. It is further supported during the senescence
maintenance phase by the upregulated expression of TRPV6,
as well as other transmembrane calcium channels and an
array of calcium signaling-involved molecules (Table 4).
V alidation of microarray data
Twenty-two genes upregulated in methotrexate-treated C85
cells of MTX48 and/or R96 treatment variant and identified
Fig. 2 SummaryofinteractionsleadingtoNF-κBactivationinC85cells
during maintenance phase of methotrexate-induced senescence. Listed
are selected molecules upregulated in senescent C85 cells whose
functional assignment was performed in IPA software. AKT protein
kinase B; AREG amphiregulin; Bcl-xL BCL2-like 1 nuclear gene
encoding mitochondrial protein (BCL2L1); BIRC3 baculoviral IAP
repeat-containing 3 apoptosis inhibitor; BMP1/2 bone morphogenetic
protein 1/2; CXCL1/3 chemokine ligand 1/3; DR3/4/5/6 death receptor
3/4/5/6; EREG epiregulin; F AS TNF receptor superfamily, member 6;
ICAM1 intracellular adhesion molecule 1; IKBKG inhibitor of kappa
light polypeptide gene enhancer in B-cells, kinase gamma; iNOS
inducible nitric oxide synthase (NOS2A); LTBR lymphotoxin beta
receptor; NFKB2 nuclear factor of kappa light polypeptide gene
enhancer in B-cells 2; NIK NFKB-inducing kinase; NRG1 neuregulin
1; PDGF A platelet-derived growth factor alpha; PLAT tissue plasmino-
gen activator; RANTES chemokine ligand 5; RELB v-rel reticuloendo-
theliosis viral oncogene homolog B; TAB2 MAP3K7-interacting protein
2; TAK1 TGF beta-activated kinase 1 (MAP3K7); TGF A transforming
growth factor alpha; TWEAK-RTNF receptor superfamily member 12A.
Corresponding microarray data are presented in Table S5
970 Tumor Biol. (2011) 32:965–976by IP A software as eligible for the activated pathways, were
chosen for their expression level measurement by quantitative
RT-PCR (Table 5). All genes tested were confirmed upregu-
lated. As only upregulated identifiers served for pathways
delineation, the study is thus considered validated.
Discussion
Functional analysis of gene expression pattern of human colon
cancer C85 cells driven into drug-induced senescence by
methotrexate treatment is described. The nitrosative/oxidative
stress associated with inflammatory functions is inferred to
determine establishment of senescent phenotype in this
cellular system. p53-dependent cell-fate decisive programs,
apoptosis and autophagy, are found to contribute to this
process. Cytoskeletal dynamics inferred to occur in senescent
C85 cells indicate motility, a phenomenon corresponding with
specificity of inflammatory cells. SASP of senescent C85 cells
consists predominantly of growth factors and pro-
inflammatory cytokines whose autocrine action is likely to
stimulate maintenance of their characteristics.
Upon genotoxic insult, p53 controls cell-fate decisive
processes, including senescence [15, 24]. An effector of
p53 signaling, p21
waf1/cip1, was shown previously to
mediate methotrexate-induced senescence in C85 cells [8,
9]. Herein identified activation of p53 signaling pathway at
the senescence initiation phase, correlated with apparent
manifestation of oxidative stress, is indicative of DNA
damage caused by ROS. Induction of oxidative stress and
accumulation of DNA damage are established manifesta-
tions of methotrexate action on various cell types [25–27].
However, in regard to methotrexate used as an anticancer
agent, depletion in DNA precursors pool, resulting from
inhibition of dihydrofolate reductase (DHFR), an enzyme
being the primary intracellular target for that drug, is
considered a prevalent cause of DNA damage [28]. As
oxidative stress in living systems is underpinned by
excessive generation of both ROS and reactive nitrogen
species (RNS), it is referred to as nitrosative/oxidative
stress, especially in regard to cells containing activated
NOS [29]. All NOS isoforms have a property to secrete,
apart from NO, also a superoxide anion [30]. In endothelial
cells under diseased states, a phenomenon of eNOS
uncoupling, i.e., superoxide production by activated eNOS,
is attributed to limited bioavailability of one of NOS
cofactors, tetrahydrobiopterin (BH4) [31]. BH4 is recycled
within a cell from dihydrobiopterin in the reaction catalyzed
by DHFR [32]. In endothelial cells, methotrexate was
demonstrated to cause, due to DHFR inhibition, eNOS
uncoupling leading to increased eNOS-dependent superox-
ide production [33]. Numerous human tumors were shown
to express different NOSs and, consequently, to secrete NO
that may show either tumor-promoting or tumor-regressive
action, with the latter proposed to be exerted by high NO
concentrations evoking DNA damage [34]. Activities of
constitutive NOSs (cNOSs), i.e., eNOS and nNOS (neuro-
nal NOS), and iNOS are inversely regulated. cNOSs
produce lower NO levels than iNOS, maintaining transcrip-
tional repression of the latter. cNOSs expression decline
Fig. 3 Summary of interactions
determining cytoskeletal rear-
rangements and cell motility in
C85 cells during maintenance
phase of methotrexte-induced
senescence. The interactions of
the “outside-in” signaling direc-
tion are marked. ECM, integrins
and focal adhesion molecules
are shown as a complex. Listed
are selected molecules upregu-
lated in senescent C85 cells
whose functional assignment
was performed in IPA software.
ERBB2 v-erb-b2 erythroblastic
leukemia viral oncogene homo-
log 2, GPCR G-protein-coupled
receptor, MET met proto-
oncogene, MYL12A/B myosin
regulatory light chain, NRP1
neuropilin 1, P AK2/6 p21-
activated kinase 2/6, PLXNB1
plexin B1, Rho ras homologue
gene family. Other abbreviations
are used as in Fig. 2.
Corresponding microarray data
are presented in Table S6
Tumor Biol. (2011) 32:965–976 971with aging and inflammation, leading to decrease in NO
level below the threshold sufficient to relieve iNOS
expression, the latter also known to be mediated by NF-
κB signaling [29, 35]. Analogous regulatory pattern of
eNOS and iNOS expression seems to operate in C85 cells
progressing into methotrexate-induced senescence (Table 5).
Detection of eNOS expression in untreated C85 cells
indicates NO to play a signaling role. At the senescence
maintenance phase, eNOS expression decreases by 3-fold
in relation to the initiation phase, and iNOS expression
undetected in the untreated cells, increases by 10-fold in
relation to the cells at the initiation phase. It is therefore
reasonable to consider that methotrexate acting as an
inhibitor of BH4 recycling leads to eNOS uncoupling
and superoxide, instead of NO, generation. Upon NO
level dropping below the threshold and due to pro-
inflammatory signaling (Figs. 2 and 4), upregulation of
iNOS expression may bring about production of toxic NO
amounts. Nitrosative/oxidative stress thus generated may
be further potentiated due to mitochondrial dysfunction
(Table 3). Thus, toxic effects of ROS/RNS may be
ultimately responsible for cellular damage and mainte-
nance of senescent phenotype of methotrexate-treated C85
cells.
The role of ROS in senescence establishment is well
documented [36–38]. According to a proposed model of a
positive feedback regulatory loop between DNA damage
and ROS generation, DNA damage-triggered p53 signal-
ing leads to cell cycle arrest exerted by p21
waf1/cip1,a n dt o
mitochondrial dysfunction resulting in ROS production,
the latter exerted by GADD45 transmitting the signal via
p38 MAPK α and transforming growth factor β (TGFβ),
and providing perpetual DNA damage stimulation [39].
p38 MAPK was proposed to define a common senescence
signaling pathway [40]. A signaling cascade mediated by
p38 MAPK β, instead of p38 MAPK α, and independent
on TGFβ, also seems to underlie maintenance of
methotrexate-induced senescence in C85 cells (Table 2,
Fig. 4). Apart from causing detrimental effects, ROS are
also known to act as secondary messengers [41]. ROS
produced by membrane NADPH oxidases are proposed to
play a primary role in propagation of growth factor- and
inflammatory cytokine-mediated signaling [41, 42]. In
accord, putative activation of NDPH–oxidase complex by
Fig. 4 Major intracellular signaling pathways coordinating mainte-
nance of methotrexate-induced senescence in C85 cells. The autocrine
action of SASP factors as well as stimulation of FAS, IL4R/IL13R,
IL22R, TLR1-3 and integrins are proposed to activate p38 MAPK β,
ERK2, ERK5 and AKT1. p38 MAPK β, ERK2 and ERK5 can also be
activated by ROS. ERK2 and ERK5 can be activated by Ca
2+. The
effector pathways include Nrf-2-mediated oxidative stress response
and NF-κB-mediated survival and NO production. The latter can be
potentiated due to EDN1 action and IFNGR1 stimulation. The
interactions shown were inferred from the following IPA canonical
signaling pathways: calcium signaling, cholecystokinin/gastrin-medi-
ated signaling, colorectal cancer metastasis signaling, endothelin 1
signaling, ERK1/2 signaling, ERK5 signaling, IL-4 signaling, IL-22
signaling, neuregulin signaling, Nrf-2-mediated oxidative stress
response, production of nitric oxide and reactive oxygen species in
macrophages, PI3K/AKT signaling, p38 MAPK signaling and xeno-
biotic signaling. CCK cholecystokinin, EDN1 endothelin 1, IFNGR1
interferon gamma receptor 1, LIF leukemia inhibitory factor. Other
abbreviations are used as in Figs. 2 and 3. Corresponding microarray
data are presented in Table S7
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treated C85 cells (Table 3), points to ROS playing a
signaling role. Inhibition of apoptosis was demonstrated to
occur due to ROS-mediated inactivation of caspase 3 [43].
In summary, in C85 cells driven into senescence by
methotrexate, ROS may (i) induce DNA damage, (ii)
propagate growth factor and cytokine signaling and (iii)
constitute one of the means to inhibit apoptosis (vide
infra).
The expression profile of p53 effector genes identified in
this study (Table 2) indicates that components of two cell-
fate decisive programs, apoptosis and autophagy, contribute
to the establishment of senescent phenotype in the cellular
system studied. Apoptosis in C85 cells treated with
methotrexate is inferred to be induced due to death receptor
signaling, as well as by oxidative stress and/or DNA
damage [14, 19]. Oxidative stress and activation of TLR
may induce autophagy [44, 45]. As senescence remains the
sole C85 cells outcome in response to methotrexate [8],
pro-apoptotic functions are apparently counteracted by anti-
apoptotic factors including Bcl-xL and cIAP member
BIRC3, or ROS (vide supra) (Table 2, Fig. 2). Involvement
of autophagy in the establishment of oncogene-induced
form of senescence was documented for human fibroblasts
[46]. In accord with both apoptosis- and autophagy-related
factors participating in the establishment of senescence in
C85 cells exposed to methotrexate, remains activation of
p38 MAPK and ERK1/2 signaling. p38 MAPK signaling is
known to mediate both cellular responses, apoptosis and
senescence [47]. ERK1/2 signaling cascade is also known
to mediate apoptosis and autophagy, as well as to underlie
senescence [48].
Activation of motile functions in senescent C85 cells
driven into senescence by methotrexate treatment
(Fig. 3), corresponds well with morphology adapted by
senescent cells of all types when cultured in vitro [5].
Also common to all senescent cells is SASP [49].
Although its composition varies among cellular systems,
it contains molecules exerting growth-promoting, growth-
suppressive and pro-inflammatory roles [3]. SASP of
senescent C85 cells consists of molecules whose autocrine
action is likely to provide growth and inflammatory
stimulation (Fig. 4). Pro-inflammatory SASP factors
identified for various senescent systems, include IL-1
and TNF molecules, as is also the case for senescent C85
cells, as well as a set of other molecules including IFNγ,
IFNβ, IL-6 or IL-8 [50, 51] .T h eu l t i m a t er o l eo fS A S Pi s
proposed to create a self-sustaining signaling loop that
assures maintenance of senescent phenotype [52], and this
is also apparent for senescent C85 cells (Fig. 4). Upregu-
lation of TLRs, known to elicit immune response not only
due to stimulation by pathogen-specific molecular patterns
[53], but also by endogenous ligands [54], indicates the
latter way of signaling to operate in senescent C85 cells.
ECM-modulating factors facilitating cell movement are
also present in SASP of those cells (Table S6). The
Table 4 Molecules involved in vitamin D receptor/retinoid receptor (VDR/RXR) and calcium signaling whose expression is upregulated in C85
cells during establishment of methotrexate-induced senescence
Functional group Molecules
VDR receptor VDR
VDR/RXR effector molecules CDKN1A, CST6, GADD45A, IGFBP3, IGFBP6, MXD1, PDGFA, PPARD, SEMA3B,
SERPINB1, TRPV6
Calcium transmembrane transporter and channels A TP2B4, CACNA1C, GRIN2C, TRPV6
Sarcoplasmic and endoplasmic reticulum calcium
transporters
A TP2A2, ITPR1, ITPR3
Calmodulin molecules CALM2, CALM3
Calcineurin molecule PPP3CC
Calcium/calmodulin-dependent protein kinases
(CaMK II)
CAMK2D, CAMK2G
cAMP-dependent protein kinases PRKAG2, PRKAR1B
The relevant molecules were inferred from the canonical VDR/RXR and calcium signaling pathways implemented in IPA software. The molecules
upregulated during both senescence initiation and maintenance phases are printed bold, upregulated during the initiation phase are printed with a
regular font and upregulated during the maintenance phase are underlined
ATP2A2/ATP2B4 A TPase calcium transporting cardiac muscle slow twitch 2/plasma membrane 4, CACNA1C voltage-dependent calcium channel
L type, CDKN1A p21
waf1/cip1, CST6 cystatin E/M, GADD45A growth arrest and DNA-damage-inducible alpha, GRIN2C glutamate receptor
(NMDAR2C), IGFBP3/6 insulin-like growth factor binding proteins 3/6, ITPR1/3 inositol 1,4,5-triphosphate receptor type 1/3, MXD1 MAX
dimerization protein 1, PDGF A platelet-derived growth factor alpha, PP ARD peroxisome proliferator-activated receptor delta, PPP3CC protein
phosphatase 3 catalytic subunit (calcineurin A gamma), PRKAG2 protein kinase AMP-activated gamma 2 non-catalytic subunit, PRKAR1B
protein kinase cAMP-dependent regulatory type I beta, SEMA3B semaphorin 3B, SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin)
member 1, TRPV6 transient receptor potential cation channel subfamily V member 6. Corresponding microarray data are presented in Table S4
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senescent C85 cells, IGFBP3 and IGFBP6 molecules
(Table 4), whose action is to inhibit insulin-like growth
factor signaling pathway.
Senescent cells are characterized by common mor-
phology and a common set of molecular markers [3].
Despite considerable variability among senescent cellular
systems, a commonality among signaling pathways regu-
lating senescence was deciphered to occur [55]. Activation
of p53, IFN, TLR, cytoskeleton reorganization, MAP
kinase and oxidative stress signaling and inhibition of
insulin growth factor-related signaling by IGFBPs, were
proposed to be critical for senescence establishment. The
results of the present study conform to that general
senescence signaling network and allow us to identify
the sets of molecules specifically involved in each
pathway execution in C85 cells driven into senescence
by methotrexate treatment. Among other signaling com-
ponents, nitric oxide, calcium, a set of cytokines including
TNF superfamily members, and hormones, are identified
as contributing to the maintenance of senescent phenotype
in those cells. Interference of methotrexate with nitric
oxide signaling emerges as a constituent of the drug
cytostatic action on colon cancer C85 cells.
Table 5 Relative gene expression levels determined by quantitative RT-PCR in C85 cells subject to methotrexate treatment and recovery
Gene name (GeneBank ID) Treatment variant
Untreated MTX48 R96
CCND2 (NM_001759) 1.93±0.05 2.63±0.14 (−/1.4) 6.09±0.61 (3.6/3.2)
CDKN1A (NM_000389) 3.25±0.21 28.03±1.52 (4.2/8.6) 28.75±0.19 (6.2/8.9)
GADD45A (NM_001924) 0.70±0.062 4.31±0.10 (4.5/6.2) 2.21±0.09 (2.4/3.2)
IL1R2 (NM_004633) 0.20±0.023 0.45±0.010 (2.4/2.3) 0.33±0.019 (1.4/1.7)
IL1RN (NM_173842) 0.14±0.001* 5.05±0.41 (3.6/36) 5.35±0.21 (3.0/38)
IRF1 (NM_002198) 0.47±0.022 1.82±0.07 (1.7/3.9) 2.08±0.09 (2.3/4.4)
ITGB4 (NM_000213) 0.53±0.052 1.40±0.01 (1.8/2.6) 0.77±0.006 (1.7/1.5)
MAP2K4 (NM_003010) 0.51±0.03 0.75±0.026 (−/1.5) 0.70±0.054 (1.9/1.4)
MAPK11 (NM_002751) 0.43±0.018 1.37±0.09 (1.8/3.2) 0.96±0.017 (1.5/2.2)
MDM2 (NM_006879, NM_002392) 1.54±0.16 8.28±0.28 (2.3/5.4; 1.6/5.4) 4.79±0.21 (1.6/3.1)
MICB (NM_05931) 0.23±0.020 0.80±0.018 (2.4/3.5) 0.35±0.013 (2.0/1.5)
NOS2A (NM_000625) undetected 1.63±0.09 (2.0/ ) 16.60±1.86 (10/ )
NOS3 (NM_000603) 0.11±0.009* 20.62±0.65 (1.5/188) 6.89±0.05 (1.3/63)
PDGFA (NM_002607) 0.24±0.013 4.72±0.47 (4.7/20) 2.15±0.10 (6.2/9.0)
PLA2G4C (NM_003706) 0.48±0.061 2.21±0.28 (1.9/4.6) 1.73±0.07 (1.8/3.6)
PSMB8 (NM_004159) 0.83±0.053 2.31±0.22 (1.4/2.8) 2.00±0.12 (1.8/2.4)
RHOF (NM_019034) 0.75±0.070 3.08±0.18 (3.6/4.1) 2.38±0.09 (2.3/3.2)
RRAS (NM_006270) 0.29±0.014 0.49±0.011 (1.6/1.7) 0.25±0.014 (−/0.9)
STA T1 (NM_007315) 0.67±0.062 3.69±0.05 (1.9/5.5) 2.76±0.12 (1.9/4.1)
TP53 (NM_000546) 1.81±0.07 1.46±0.08 (−/0.8) 1.03±0.04 (−/0.6)
UBD (NM_006398) 0.34±0.025* 1.14±0.011 (−/3.4) 39.90±1.47 (25.2/117)
VCL (NM_014000) 3.30±0.30 5.06±0.25 (−/1.5) 4.55±0.06 (2.3/1.4)
Average 2exp−ΔCT values ± SD from triplicates are presented. Asterisks indicate gene expression level detected below the 32nd cycle.
Correlations between fold change in gene expression level for particular treatment variant, determined by microarray vs. quantitative RT-PCR
approach, are shown in parentheses by two values, respectively. Hyphen indicates that gene expression level was not found changing by
microarray approach. Two GeneBank accession numbers provided at MDM2 gene refer to MDM2b and MDM2 transcript variants as primers used
were complementary to both. The following pathway-eligible molecules were included in the analysis: (i) cell cycle: CCND2 cyclin D2; CDKN1A
p21
waf1/cip1; GADD45A growth arrest and DNA-damage-inducible, alpha; MDM2 p53 binding protein, transcript variants MDM2b and MDM2;
PDGF A platelet-derived growth factor, alpha; RRAS related RAS viral (r-ras) oncogene homolog; TP53 tumor protein p53; (ii) cytoskeletal
dynamics: ITGB4 integrin beta 4; RHOF ras homolog gene family member F; VCL vinculin; (iii) IFN signaling: IRF1 interferon regulatory factor
1; MICB MHC class I polypeptide-related sequence B; PSMB8 proteasome subunit, beta type, 8; STAT1 signal transducer and activator of
transcription 1; (iv) IL-1 signaling: IL1R2 interleukin 1 receptor, type II; IL1RN interleukin 1 receptor antagonist; (v) MAP kinase signaling:
MAP2K4 mitogen-activated protein kinase kinase 4 (MKK4); MAPK11 mitogen-activated protein kinase 11 (p38 MAPK β); PLA2G4C
phospholipase A2, group IVC; (vi) nitric oxide production: NOS2A inducible NOS (iNOS); NOS3, endothelial NOS (eNOS); (vii) protein
ubiquitination: UBD ubiquitin D
974 Tumor Biol. (2011) 32:965–976Conflicts of interest None
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Blagosklonny MV . Cell senescence and hypermitogenic arrest.
EMBO Rep. 2003;4:358–62.
2. d’Adda di Fagagna F. Living on a break: cellular senescence as a
DNA-damage response. Nat Rev Cancer. 2008;8:512–22.
3. Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad
things happen to good cells. Nat Rev Mol Cell Biol. 2007;8:729–40.
4. Gewirtz DA, Holt SE, Elmore LW. Accelerated senescence: an
emerging role in tumor cell response to chemotherapy and
radiation. Biochem Pharmacol. 2008;76:947–57.
5. Collado M, Serrano M. Senescence in tumours: evidence from
mice and humans. Nat Rev Cancer. 2010;10:51–7.
6. Gewirtz DA. Autophagy, senescence and tumor dormancy in
cancer therapy. Autophagy. 2009;5:1232–4.
7. Dabrowska M, Hendrikx PJ, Skierski J, Malinowska M, Bertino
JR, Rode W. EGFP fluorescence as an indicator of cancer cells
response to methotrexate. Eur J Pharmacol. 2007;555:93–9.
8. Dabrowska M, Mosieniak G, Skierski J, Sikora E, Rode W.
Methotrexate-induced senescence in human adenocarcinoma cells
is accompanied by induction of p21
waf1/cip1 expression and lack of
polyploidy. Cancer Lett. 2009;284:95–101.
9. Dabrowska M, Skoneczny M, Mosieniak G, Sikora E, Rode W.
Expression of cell cycle checkpoints regulatory genes during
methotrexate-induced senescence in human adenocarcinoma cells.
Pteridines. 2009;20:143–7.
10. Copeland NG, Jenkins NA. Deciphering the genetic landscape
of cancer-from genes to pathways. Trends Genet. 2009;
25:455–62.
11. Swanton C, Caldas C. Molecular classification of solid tumors:
towards pathway-driven therapeutics. Br J Cancer. 2009;
100:1517–22.
12. Longo GSA, Izzo J, Gorlick JR, Banerjee D, Jhanwar SC, Bertino
JR. Characterization and drug sensitivity of four newly established
colon adenocarcinoma cell lines to antifolate inhibitors of
thymidylate synthase. Oncol Res. 2000;12:309–14.
13. Zelcer S, Kellick M, Wexler LH, Gorlick R, Meyers PA. The
Memorial Sloan Kettering Cancer Center experience with outpa-
tient administration of high dose methotrexate with leucovorin
rescue. Pediatr Blood Cancer. 2008;50:1176–80.
14. Polyak K, Xia Y , Zweier JL, Kinzler KW, V ogelstein A. A model
for p53-induced apoptosis. Nature. 1997;389:300–5.
15. V ousden KH, Lane DP . p53 in health and disease. Nat Rev Mol
Cell Biol. 2007;8:275–83.
16. Kumar MJ, Nicholls DG, Andersen JK. Oxidative α-ketoglutarate
dehydrogenase inhibition via subtle elevations in monoamine
oxidase B levels results in loss of spare respiratory capacity. J Biol
Chem. 2003;278:46432–9.
17. Manoli I, Le H, Alesci S, McFann KK, Su Y A, Kino T, et al.
Monoamine oxidase-A is a major target gene for glucocorticoids
in human skeletal muscle cells. FASEB J. 2005;19:1359–61.
18. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology,
pathophysiology,andpharmacology.PharmacolRev.1991;43:109–42.
19. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME.
Apoptosis signaling by death receptors. Eur J Biochem.
1998;254:439–59.
20. Mruk DD, Cheng CY . Sertoli–Sertoli and Sertoli–germ cell
interactions and their significance in germ cell movement in the
seminiferous epithelium during spermatogenesis. Endocr Rev.
2004;25:747–806.
21. Dasari A, Bartholomew JN, V olonte D, Galbiati F. Oxidative stress
induces premature senescence by stimulating caveolin-1 gene
transcription through p38 mitogen-activated protein kinase/Sp1-
mediated activation of two GC-rich promoter elements. Cancer
Res. 2006;66:10805–14.
22. Khan EM, Heidinger JM, Levy M, Lisanti MP , Ravid T, Goldkorn
T. Epidermal growth factor receptor exposed to oxidative stress
undergoes src- and caveolin-1-dependent perinuclear trafficking. J
Biol Chem. 2006;281:14486–93.
23. Ravikumar B, Moreau K, Jahreiss L, Puri C, Rubinsztein DC.
Plasma membrane contributes to the formation of pre-
autophagosomal structures. Nat Cell Biol. 2010;12:747–57.
24. Zhang H. Molecular signaling and genetic pathways of senes-
cence: its role in tumorigenesis and ageing. J Cell Physiol.
2007;210:567–74.
25. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces
apoptosis with reactive oxygen species involvement in T
lymphocytic cell lines to a greater extent than in monocytic lines.
Inflamm Res. 2005;54:273–80.
26. Martin SA, McCarthy A, Barber LJ, Burgess DJ, Parry S, Lord
CJ, et al. Methotrexate induces oxidative damage and is
selectively lethal to tumour cells with defects in the DNA
mismatch repair gene MSH2. EMBO Mol Med. 2009;1:323–37.
27. Robaey P , Krajinovic M, Marcoux S, Moghrabi A. Pharmacoge-
netics of the neurodevelopmental impact of anticancer chemo-
therapy. Dev Disabil Res Rev. 2008;14:211–20.
28. Kinsella AR, Smith D, Pickard M. Resistance to chemothera-
peutic antimetabolites: a function of salvage pathway involve-
ment and cellular response to DNA damage. Br J Cancer. 1997;
75:935–45.
29. Mariotto S, Miscusi M, Persichini T, Colasanti M, Suzuki H.
Ageing-related role of nitric oxide in the brain. In: Straub RH,
Mochegiani E, editors. The neuroendocrine immune network in
ageing. Elsevier B.V ., Amsterdam, The Netherlands; 2004. pp
291–300.
30. Stuehr D, Pou S, Rosen GM. Oxygen reduction by nitric-oxide
synthases. J Biol Chem. 2001;276:14533–6.
31. Cosentino F, Luscher TF. Tetrahydrobiopterin and endothelial
nitric oxide synthase activity. Cariovascular Res. 1999;43:274–8.
32. Hasegawa H, Sawabe K, Nakanishi N, Wakasugi OK. Delivery of
exogenous tetrahydrobiopterin (BH4) to cells of target organs: role
of salvage pathway and uptake of its precursor in effective
elevation of tissue BH4. Mol Genet Metab. 2005;86:S2–10.
33. Crabtree MJ, Tatham AL, Hale AB, Alp NJ, Channon KM.
Critical role for tetrahydrobiopterin recycling by dihydrofo-
late reductase in regulation of endothelial nitric-oxide syn-
thase coupling: relative importance of the de novo biopterin
synthesis versus salvage pathways. J Biol Chem.
2009;284:28128–36.
34. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in
tumor progression. Nat Rev Cancer. 2006;6:521–34.
35. Colasanti M, Suzuki H. The dual personality of NO. Trends
Pharmacol Sci. 2000;21:249–52.
36. Passos JF, von Zglinicki T. Oxygen free radicals in cell
senescence: are they signal transducers? Free Radic Res.
2006;40:1277–83.
37. Passos JF, Saretzki G, Ahmed S, Richter T, Peters H, Wappler
I, et al. Mitochondrial dysfunction accounts for the stochastic
heterogeneity in telomere-dependent senescence. PLOS.
2007;5:e110.
38. Ramsey MR, Sharpless NE. ROS as a tumor suppressor? Nat Cell
Biol. 2006;8:1213–5.
Tumor Biol. (2011) 32:965–976 97539. Passos JF, Nelson G, Wang C, Richter T, Simillion C, Proctor CJ,
et al. Feedback between p21 and reactive oxygen production is
necessary for cell senescence. Mol Syst Biol. 2010;6:347.
40. Iwasa H, Han J, Ishikawa F. Mitogen-activated protein kinase p38
defines the common senescence-signalling pathway. Genes Cells.
2003;8:131–44.
41. Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as
intracellular messengers during cell growth and differentiation.
Cell Physiol Biochem. 2001;11:173–86.
42. Woo HA, Yim SH, Shin DH, Kang D, Y u DY ,R h e eS G .
Inactivation of peroxiredoxin I by phosphorylation allows
localized H2O2 accumulation for cell signaling. Cell. 2010;
140:517–28.
43. Choi K, Ryu SW, Song S, Choi H, Kang SW, Choi C. Caspase-
dependent generation of reactive oxygen species in human
astrocytoma cells contributes to resistance to TRAIL-mediated
apoptosis. Cell Death Differ. 2010;17:833–45.
44. Delgado MA, Deretic V . Toll-like receptors in control of
immunological autophagy. Cell Death Differ. 2009;16:976–83.
45. Scherz-Shouval R, Elazar Z. ROS, mitochondria and the regula-
tion of autophagy. Trends Cell Biol. 2007;17:422–7.
46. Y oung ARJ, Narita M, Ferreira M, Kirschner K, Sadaie M, Darot
JFJ, et al. Autophagy mediates the mitotic senescence transition.
Genes Dev. 2009;23:798–803.
47. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase
pathway. Cell Res. 2005;15:11–8.
48. Cagnol S, Chambard JC. ERK and cell death: Mechanisms of
ERK-induced cell death—apoptosis, autophagy and senescence.
FEBS J. 2009;277:2–21.
49. Fumagali M, d’Adda di Fagagna F. SASPense and DDRama in
cancer and ageing. Nat Cell Biol. 2009;11:921–3.
50. Rodier F, Coppe JP , Patil CK, Hoeijmakers W A, Munoz DP , Raza
SR, et al. Persistent DNA damage signaling triggers senescence-
associated inflammatory cytokine secretion. Nat Cell Biol.
2009;11:973–81.
51. Novakova Z, Hubackova S, Kosar M, Janderova-Rossmeislova L,
Dobrovolna J, V asicova P , et al. Cytokine expression and signaling
in drug-induced cellular senescence. Oncogene. 2010;29:273–84.
52. Bartek J, Hodny Z, Lukas J. Cytokine loops driving senescence.
Nat Cell Biol. 2008;10:887–9.
53. Abreu MT. Toll-like receptor signaling in the intestinal epithelium:
how bacterial recognition shapes intestinal function. Nat Rev
Immunol. 2010;10:131–43.
54. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F,
Zitvogel L, et al. Molecular characteristics of immunogenic cancer
cell death. Cell Death Differ. 2008;15:3–12.
55. Fridman AL, Tainsky MA. Critical pathways in cellular senes-
cence and immortalization revealed by gene expression profiling.
Oncogene. 2008;27:5975–87.
56. Levine B, Klionsky DJ. Development by self-digestion: molecular
mechanisms and biological functions of autophagy. Dev Cell.
2004;6:463–77.
976 Tumor Biol. (2011) 32:965–976